ArticleEuropean biophysics journal : EBJ2017
Effect of pH and ionic strength on the binding strength of anti-PF4/polyanion antibodies.
Article in European biophysics journal : EBJ, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Advances in our understanding of anti-PF4 related immunothrombosis.Frontiers in immunology · 2025Review
- The Binding of the SARS-CoV-2 Spike Protein to Platelet Factor 4: A Proposed Mechanism for the Generation of Pathogenic Antibodies.Biomolecules · 2024Article
- Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.Blood advances · 2022Article
- Ionic strength-sensitive and pH-insensitive interactions between C-reactive protein (CRP) and an anti-CRP antibody.Biophysics and physicobiology · 2022Article
- Label-Free Detection and Characterization of Heparin-Induced Thrombocytopenia (HIT)-like Antibodies.ACS omega · 2021Article
- Colloidal Gold Immunochromatographic Assay for Rapid Detection of Carbadox and Cyadox in Chicken Breast.ACS omega · 2020Article
- The Role of Single-Molecule Force Spectroscopy in Unraveling Typical and Autoimmune Heparin-induced Thrombocytopenia.International journal of molecular sciences · 2018Review
- Regional Biophysics Conference - RBC2016.European biophysics journal : EBJ · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Antibodies against the chemokine platelet factor 4 (PF4) in complex with heparin cause the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT). The current dilemma for laboratory diagnosis of HIT is that only about 50% of these antibodies are pathogenic, but the widely available enzyme immunosorbent assays (EIA), used for diagnosis in the clinical laboratory cannot differentiate between non-pathogenic- and pathogenic (platelet activating) antibodies. It would be highly desirable to improve diagnosis for HIT. Here, we use single-molecule force spectroscopy to identify conditions at which non-pathogenic antibodies show a different reactivity pattern compared to pathogenic antibodies. At physiological conditions (pH 7.4, 150 mM NaCl), non-pathogenic antibodies bound to PF4/heparin complexes with weaker binding forces than pathogenic ones. Binding forces measured over a wide range of pH or ionic strength show that non-pathogenic antibodies are not significantly affected by environmental changes, whereas pathogenic antibodies are. Based on the dissimilar behavior of these antibodies at 500 mM salt, we performed a PF4/heparin EIA at this condition and observed that optical density of non-pathogenic antibodies slightly reduced while it drastically reduced for pathogenic antibodies. Our results suggest that the specificity of anti-PF4/heparin EIAs for clinically relevant antibodies can be improved by changing test conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.